(P12-016-23) Weight Loss in Patients With COVID-19 and Influenza in Comorbidity With Non-Communicable Chronic Diseases: A Pilot Prospective Clinical Trial

Objectives: To evaluate the effects of the fast weight loss method on clinic/laboratory inflammation and metabolic profile, reactive oxygen species (ROS) body composition in patients with COVID-19/Influenza in comorbidity with non-communicable chronic diseases (NCDs)

Methods: A 6-week open, pilot prospective clinical trial. The study included 62 adult patients with COVID-19 (27) and Influenza (35) in comorbidity with type 2 diabetes (T2D), hypertension, and non-alcohol steatohepatitis (NASH).

Interventions: The fast-weight-loss-method (Analimentary detoxication, ANADETO) including calorie restriction to 50-100 kcal/day, salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day, walking >2,000 steps/day, and sexual self-restraint.

Main outcome measures: Primary endpoints: Clinic/infectious/inflammation tests for COVID/Influenza; weight loss during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin; systolic/diastolic BP; blood lipids; ALT/AST, chest-CT-scan.

Results: The patients weight lost from baseline (-9,14-12,4%; P < 0.001); COVID and Influenza were a negative in >96.3% patients at the 14 days. Systolic/diastolic BP normalized (P < 0.0001), glucose/lipids metabolism (P < 0.0001); ALT/AST normalized (P < 0.0001), platelets increased from baseline (P < 0.0001), chest-CT (P < 0.0001) at 6-week follow-up. The previous antidiabetic, antihypertensive, anti-inflammatory and hepatoprotective, and other symptomatic medications were adequately decreased in 2-5 days to completely stopping by 5-8 days treatment.

Conclusions: The fast weight loss (ANADETO) is clinical/laboratory benefit in treatment of patients with COVID-19 or Influenza in comorbidity with T2D, hypertension, and NASH.

Funding Sources: This research was supported by Ministry of Education and Science of the Republic of Kazakhstan.